Christy Maksoudian

Christy Maksoudian

Auto-generated profile, based on publicly available information

Christy Maksoudian

NanoHealth and Optical Imaging Group, Department of Imaging and Pathology, KULeuven, Herestraat 49, B3000 Leuven, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Chemical Reviews
Verified
Journal Article
Open access
MIMukaddes Izci
Mukaddes Izci
CMChristy Maksoudian
Christy Maksoudian
Bella Barjouhi ManshianBella Barjouhi Manshian
Bella Barjouhi Manshian
Stefaan J.H. SoenenStefaan J.H. Soenen
Stefaan J.H. Soenen
Nanomaterial (NM) delivery to solid tumors has been the focus of intense research for over a decade. Classically, scientists have tried to improve NM delivery by employing passive or active targeting strategies, making use of the so-called enhanced permeability and retention (EPR) effect. This phenomenon is made possible due to the leaky tumor vasculature through which NMs can leave the bloodstream, traverse through the gaps in the endothelial lining of the vessels, and enter the tumor. Recent studies have shown that despite many efforts to employ the EPR effect, this process remains very poor. Furthermore, the role of the EPR effect has been called into question, where it has been suggested that NMs enter the tumor via active mechanisms and not through the endothelial gaps. In this review, we provide a short overview of the EPR and mechanisms to enhance it, after which we focus on alternative delivery strategies that do not solely rely on EPR in itself but can offer interesting pharmacological, physical, and biological solutions for enhanced delivery. We discuss the strengths and shortcomings of these different strategies and suggest combinatorial approaches as the ideal path forward.

27 July 2020 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
CMChristy Maksoudian
Christy Maksoudian
NSNeshat Saffarzadeh
Neshat Saffarzadeh
EHEvelien Hesemans
Evelien Hesemans
NDNora Dekoning
Nora Dekoning
KBKiana Buttiens
Kiana Buttiens
Stefaan J.H. SoenenStefaan J.H. Soenen
Stefaan J.H. Soenen
Nanomaterials are currently widely exploited for their potential in the development of novel cancer therapies, and so far, mainly nanoparticles (NPs) consisting of liposomes and polymers have made their way into the clinic. However, major bottlenecks for the clinical translation of other types of NPs (i.e. inorganic) are the lack of knowledge concerning their long-term distribution in vivo and their potential toxicity. To counter this, various research groups have worked on soluble NPs, such as zinc oxide (ZnO), copper oxide (CuO), and silver (Ag), which tend to dissolve spontaneously into their ionic form, releasing toxic metal ions and leading to reactive oxygen species (ROS) generation when exposed to cellular environments. By fine-tuning the dissolution kinetics of these NPs, it is possible to control the level of ROS production and thus cytotoxicity to selectively destroy tumor tissue. Specifically, cancer cells tend to exhibit a higher basal level of oxidative stress compared to normal cells due to their higher metabolic rates, and therefore, by engineering NPs that generate sufficient ROS that barely exceed toxic thresholds in cancer cells, normal cells will only experience reversible transient damage. This review focuses on the use of these soluble inorganic NPs for selective cancer therapy and on the various in vitro and in vivo studies that have aimed to control the dissolution kinetics of these NPs, either through particle doping or surface modifications.

15 April 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ACAlexander M. Cryer
Alexander M. Cryer
CCCheuk Chan
Cheuk Chan
AEAnastasia Eftychidou
Anastasia Eftychidou
CMChristy Maksoudian
Christy Maksoudian
MMMohan Mahesh
Mohan Mahesh
ATAndrew J. Thorley
Andrew J. Thorley

4 January 2023 in EMBO Reports
Verified
Journal Article
Open access
KAKourosh Ahmadzadeh
Kourosh Ahmadzadeh
MPMarie Pereira
Marie Pereira
MVMargot Vanoppen
Margot Vanoppen
EBEline Bernaerts
Eline Bernaerts
JKJeong-Hun Ko
Jeong-Hun Ko
JBJacques Behmoaras
Jacques Behmoaras
Macrophages undergo plasma membrane fusion and cell multinucleation to form multinucleated giant cells (MGCs) such as osteoclasts in bone, Langhans giant cells (LGCs) as part of granulomas or foreign‐body giant cells (FBGCs) in reaction to exogenous material. How multinucleation per se contributes to functional specialization of mature mononuclear macrophages remains poorly understood in humans. Here, we integrate comparative transcriptomics with functional assays in purified mature mononuclear and multinucleated human osteoclasts, LGCs and FBGCs. Strikingly, in all three types of MGCs, multinucleation causes a pronounced downregulation of macrophage identity. We show enhanced lysosome‐mediated intracellular iron homeostasis promoting MGC formation. The transition from mononuclear to multinuclear state is accompanied by cell specialization specific to each polykaryon. Enhanced phagocytic and mitochondrial function associate with FBGCs and osteoclasts, respectively. Moreover, human LGCs preferentially express B7‐H3 (CD276) and can form granuloma‐like clusters in vitro , suggesting that their multinucleation potentiates T cell activation. These findings demonstrate how cell–cell fusion and multinucleation reset human macrophage identity as part of an advanced maturation step that confers MGC‐specific functionality.

25 March 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
CMChristy Maksoudian
Christy Maksoudian
Stefaan J.H. SoenenStefaan J.H. Soenen
Stefaan J.H. Soenen
KSKimihiro Susumu
Kimihiro Susumu
EOEunkeu Oh
Eunkeu Oh
Igor MedintzIgor Medintz
Igor Medintz
Bella Barjouhi ManshianBella Barjouhi Manshian
Bella Barjouhi Manshian

1 January 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
KBKiana Buttiens
Kiana Buttiens
CMChristy Maksoudian
Christy Maksoudian
IGIrati Perez Gilabert
Irati Perez Gilabert
CLCarla Rios Luci
Carla Rios Luci
Bella Barjouhi ManshianBella Barjouhi Manshian
Bella Barjouhi Manshian
Stefaan J.H. SoenenStefaan J.H. Soenen
Stefaan J.H. Soenen